New drug combo shows promise for tough blood cancers
NCT ID NCT05428969
First seen Dec 10, 2025 · Last updated May 20, 2026 · Updated 24 times
Summary
This study tests a new drug called bexmarilimab combined with standard treatments for people with certain blood cancers (MDS, CMML, or AML). The goal is to find a safe dose and see if the combination helps control the disease. About 181 adults will take part, and the study is currently active but not recruiting new participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
City of Hope National Medical Center
Duarte, California, 91010, United States
-
Helsinki University Hospital
Helsinki, 00029, Finland
-
Kuopio University Hospital
Kuopio, 70210, Finland
-
Oulu University Hospital
Oulu, 90029, Finland
-
Royal Cornwall Hospitals NHS Trust
Truro, United Kingdom
-
Tampere University Hospital
Tampere, 33520, Finland
-
The Christie NHS Foundation Trust
Manchester, United Kingdom
-
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, 27599, United States
-
University of Texas, MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Yale Cancer Center
New Haven, Connecticut, 06510, United States
Conditions
Explore the condition pages connected to this study.